The therapeutic monoclonal antibody cetuximab is among the latest arsenal developed for war on cancer, designed to block tumor growth by specifically targeting the extracellular domain of EGFR on the surface of cancer cells. Alarmingly, resistance to cetuximab has been observed. Using peptides containing methylated arginine residues synthesized by LifeTein to generated specific antibodies in mice, the researchers were able to pinpoint Arg198 and Arg200 of EGFR were methylated by protein arginine methyltransferase 1 (PRMT1) in colorectal cancer cells, which could be critical for cetuximab resistance. Their results paved a way for developing better treatment for cancer patients.
Antibody Therapy & Colorectal Cancer
The Journal of Clinical Investigation. 2015;125(12):4529-4543. doi:10.1172/JCI82826. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.